News
RAPT hit by FDA clinical hold on eczema, asthma drug
RAPT Therapeutics has seen its shares fall sharply after the FDA placed a clinical hold on oral CCR4 antagonist zelnecirnon, currently in a phase 2b trial for atopic derma
